Orthogonal dual reporter-based gain-of-signal assay for probing SARS-CoV-2 3CL protease activity in living cells: inhibitor identification and mutation investigation

References

• Saxena SK, Kumar S, Ansari S, et al. Characterization of the novel SARS-CoV-2 Omicron (B.1.1.529) variant of concern and its global perspective. J Med Virol. 2022;94(4):1738–1744.
   PubMed Web of Science ®Google Scholar
• Andeweg SP, de Gier B, Eggink D, et al. Protection of COVID-19 vaccination and previous infection against Omicron BA.1, BA.2 and Delta SARS-CoV-2 infections. Nat Commun. 2022;13(1):4738.
   PubMed Web of Science ®Google Scholar
• Stevens LJ, Pruijssers AJ, Lee HW, et al. Mutations in the SARS-CoV-2 RNA-dependent RNA polymerase confer resistance to remdesivir by distinct mechanisms. Sci Transl Med. 2022;14(656):eabo0718.
   PubMed Web of Science ®Google Scholar
• Hu Y, Lewandowski EM, Tan H, et al. Naturally occurring mutations of SARS-CoV-2 main protease confer drug resistance to nirmatrelvir. bioRxiv [Preprint]. 2022:2022.06.28.497978.
   Google Scholar
• Roe MK, Junod NA, Young AR, et al. Targeting novel structural and functional features of coronavirus protease nsp5 (3CLpro, Mpro) in the age of COVID-19. J Gen Virol. 2021;102(3):001558.
   PubMed Web of Science ®Google Scholar
• Anand K, Ziebuhr J, Wadhwani P, et al. Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science. 2003;300(5626):1763–1767.
   PubMed Web of Science ®Google Scholar
• Yang H, Xie W, Xue X, et al. Design of wide-spectrum inhibitors targeting coronavirus main proteases. PLoS Biol. 2005;3(10):e324.
   PubMed Web of Science ®Google Scholar
• Therapeutics and COVID-19: living guideline, 13 January 2023. Geneva: World Health Organization; 2023 (WHO/2019-nCoV/therapeutics/2023.1).
   Google Scholar
• Owen DR, Allerton CMN, Anderson AS, et al. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19. Science. 2021;374(6575):1586–1593.
   PubMed Web of Science ®Google Scholar
• Ma C, Sacco MD, Hurst B, et al. Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease. Cell Res. 2020;30(8):678–692.
   PubMed Web of Science ®Google Scholar
• Jin Z, Du X, Xu Y, et al. Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature. 2020;582(7811):289–293.
   PubMed Web of Science ®Google Scholar
• Drayman N, DeMarco JK, Jones KA, et al. Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2. Science. 2021;373(6557):931–936.
   PubMed Web of Science ®Google Scholar
• Unoh Y, Uehara S, Nakahara K, et al. Discovery of S-217622, a noncovalent oral SARS-CoV-2 3CL protease inhibitor clinical candidate for treating COVID-19. J Med Chem. 2022;65(9):6499–6512.
   PubMed Web of Science ®Google Scholar
• Günther S, Reinke PYA, Fernández-García Y, et al. X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease. Science. 2021;372(6542):642–646.
   PubMed Web of Science ®Google Scholar
• Cao W, Cho CD, Geng ZZ, et al. Evaluation of SARS-CoV-2 main protease inhibitors using a novel cell-based assay. ACS Cent Sci. 2022;8(2):192–204.
   PubMed Web of Science ®Google Scholar
• Ma C, Tan H, Choza J, et al. Validation and invalidation of SARS-CoV-2 main protease inhibitors using the Flip-GFP and Protease-Glo luciferase assays. Acta Pharm Sin B. 2022;12(4):1636–1651.
   PubMed Web of Science ®Google Scholar
• Froggatt HM, Heaton BE, Heaton NS. Development of a fluorescence-based, high-throughput SARS-CoV-2 3CLpro reporter assay. J Virol. 2020;94(22):e01265–20.
   PubMed Web of Science ®Google Scholar
• O’Brien A, Chen DY, Hackbart M, et al. Detecting SARS-CoV-2 3CLpro expression and activity using a polyclonal antiserum and a luciferase-based biosensor. Virology. 2021;556:73–78.
   PubMed Web of Science ®Google Scholar
• Hou N, Peng C, Zhang L, et al. BRET-based self-cleaving biosensors for SARS-CoV-2 3CLpro inhibitor discovery. Microbiol Spectr. 2022;10(4):e0255921.
   PubMed Web of Science ®Google Scholar
• Rawson JMO, Duchon A, Nikolaitchik OA, et al. Development of a cell-based luciferase complementation assay for identification of SARS-CoV-2 3CLpro inhibitors. Viruses. 2021;13(2):173.
   PubMed Web of Science ®Google Scholar
• Dey-Rao R, Smith GR, Timilsina U, et al. A fluorescence-based, gain-of-signal, live cell system to evaluate SARS-CoV-2 main protease inhibition. Antiviral Res. 2021;195:105183.
   PubMed Web of Science ®Google Scholar
• Moghadasi SA, Esler MA, Otsuka Y, et al. Gain-of-signal assays for probing inhibition of SARS-CoV-2 Mpro/3CLpro in living cells. mBio. 2022;13(3):e0078422.
   PubMed Web of Science ®Google Scholar
• Resnick SJ, Iketani S, Hong SJ, et al. Inhibitors of coronavirus 3CL proteases protect cells from protease-mediated cytotoxicity. J Virol. 2021;95(14):e0237420.
   PubMed Web of Science ®Google Scholar
• Ullrich S, Ekanayake KB, Otting G, et al. Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir. Bioorg Med Chem Lett. 2022;62:128629.
   PubMed Web of Science ®Google Scholar
• Sacco MD, Hu Y, Gongora MV, et al. The P132H mutation in the main protease of Omicron SARS-CoV-2 decreases thermal stability without compromising catalysis or small-molecule drug inhibition. Cell Res. 2022;32(5):498–500.
   PubMed Web of Science ®Google Scholar
• Zhang JH, Chung TD, Oldenburg KR. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen. 1999;4(2):67–73.
   PubMed Web of Science ®Google Scholar
• R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2022. Available from: https://www.R-project.org/
   Google Scholar
• Ritz C, Baty F, Streibig JC, et al. Dose-response analysis using R. PLoS One. 2015;10(12):e0146021.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Fang C, Zhang Q, et al. Crystal structure of SARS-CoV-2 main protease in complex with protease inhibitor PF-07321332. Protein Cell. 2022;13(9):689–693.
   PubMed Web of Science ®Google Scholar
• Lin CW, Lin KH, Hsieh TH, et al. Severe acute respiratory syndrome coronavirus 3C-like protease-induced apoptosis. FEMS Immunol Med Microbiol. 2006;46(3):375–380.
   PubMedGoogle Scholar
• Yao K, Wang K, Xu W, et al. Caspase-3 and its inhibitor Ac-DEVD-CHO in rat lens epithelial cell apoptosis induced by hydrogen in vitro. Chin Med J (Engl). 2003;116(7):1034–1038.
   PubMed Web of Science ®Google Scholar
• Teng JF, Mei QB, Zhou XG, et al. Polyphyllin VI induces caspase-1-mediated pyroptosis via the induction of ROS/NF-κB/NLRP3/GSDMD signal axis in non-small cell lung cancer. Cancers (Basel). 2020;12(1):193.
   PubMed Web of Science ®Google Scholar
• Zhang S, Wang J, Cheng G. Protease cleavage of RNF 20 facilitates coronavirus replication via stabilizaiton of SREBP1. Proc Natl Acad Sci U S A. 2021;118(37):e2107108118.
   PubMed Web of Science ®Google Scholar
• Meyer B, Chiaravalli J, Gellenoncourt S, et al. Characterising proteolysis during SARS-CoV-2 infection identifies viral cleavage sites and cellular targets with therapeutic potential. Nat Commun. 2021;12(1):5553.
   PubMed Web of Science ®Google Scholar
• Moustaqil M, Ollivier E, Chiu HP, et al. SARS-CoV-2 proteases PLpro and 3CLpro cleave IRF3 and critical modulators of inflammatory pathways (NLRP12 and TAB1): implications for disease presentation across species. Emerg Microbes Infect. 2021;10(1):178–195.
   PubMed Web of Science ®Google Scholar
• Pablos I, Machado Y, de Jesus HCR, et al. Mechanistic insights into COVID-19 by global analysis of the SARS-CoV-2 3CLpro substrate degradome. Cell Rep. 2021;37(4):109892.
   PubMed Web of Science ®Google Scholar
• Koudelka T, Boger J, Henkel A, et al. N-Terminomics for the identification of in vitro substrates and cleavage site specificity of the SARS-CoV-2 main protease. Proteomics. 2021;21(2):e2000246.
   PubMed Web of Science ®Google Scholar
• Weglarz-Tomczak E, Tomczak JM, Talma M, et al. Identification of ebselen and its analogues as potent covalent inhibitors of papain-like protease from SARS-CoV-2. Sci Rep. 2021;11(1):3640.
   PubMed Web of Science ®Google Scholar
• Strobelt R, Adler J, Paran N, et al. Imatinib inhibits SARS-CoV-2 infection by an off-target-mechanism. Sci Rep. 2022;12(1):5758.
   PubMed Web of Science ®Google Scholar
• Gangavarapu K, Latif AA, Mullen JL, et al. Outbreak.info genomic reports: scalable and dynamic surveillance of SARS-CoV-2 variants and mutations. Nat Methods. 2023. doi:10.1038/s41592-023-01769-3
   Web of Science ®Google Scholar
• Sampah ME, Shen L, Jilek BL, et al. Dose-response curve slope is a missing dimension in the analysis of HIV-1 drug resistance. Proc Natl Acad Sci U S A. 2011;108(18):7613–7618.
   PubMed Web of Science ®Google Scholar
• Abe K, Kabe Y, Uchiyama S, et al. Pro108Ser mutation of SARS-CoV-2 3CLpro reduces the enzyme activity and ameliorates the clinical severity of COVID-19. Sci Rep. 2022;12(1):1299.
   PubMed Web of Science ®Google Scholar
• FDA, Fact sheet for healthcare providers: emergency use authorization for Paxlovid (2023); Available from: https://www.fda.gov/media/155050/download
   Google Scholar
• MacDonald EA, Frey G, Namchuk MN, et al. Recognition of divergent viral substrates by the SARS-CoV-2 main protease. ACS Infect Dis. 2021;7(9):2591–2595.
   PubMed Web of Science ®Google Scholar
• Aurora R, Srinivasan R, Rose GD. Rules for alpha-helix termination by glycine. Science. 1994;264(5162):1126–1130.
   PubMed Web of Science ®Google Scholar
• Aurora R, Rose GD. Helix capping. Protein Sci. 1998;7(1):21–38.
   PubMed Web of Science ®Google Scholar
• Thomas ST, Loladze VV, Makhatadze GI. Hydration of the peptide backbone largely defines the thermodynamic propensity scale of residues at the C’ position of the C-capping box of alpha-helices. Proc Natl Acad Sci U S A. 2001;98(19):10670–10675.
   PubMed Web of Science ®Google Scholar
• Ho PI, Yue K, Pandey P, et al. Reporter enzyme inhibitor study to aid assembly of orthogonal reporter gene assays. ACS Chem Biol. 2013;8(5):1009–1017.
   PubMed Web of Science ®Google Scholar
• Iketani S, Mohri H, Culbertson B, et al. Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir. Nature. 2023;613(7944):558–564.
   PubMed Web of Science ®Google Scholar
• Shuai H, Chan JF, Hu B, et al. Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron. Nature. 2022;603(7902):693–699.
   PubMed Web of Science ®Google Scholar
• Wolter N, Jassat W, Walaza S, et al. Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant in South Africa: a data linkage study. Lancet. 2022;399(10323):437–446.
   PubMed Web of Science ®Google Scholar
• Jochmans D, Liu C, Donckers K, et al. The substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro are selected by a protease inhibitor in vitro and confer resistance to nirmatrelvir. mBio. 2023;14(1):e0281522.
   PubMed Web of Science ®Google Scholar
• Heilmann E, Costacurta F, Moghadasi SA, et al. SARS-CoV-2 3CLpro mutations selected in a VSV-based system confer resistance to nirmatrelvir, ensitrelvir, and GC376. Sci Transl Med. 2023;15(678):eabq7360.
   PubMed Web of Science ®Google Scholar
• Charness ME, Gupta K, Stack G, et al. Rebound of SARS-CoV-2 infection after nirmatrelvir-ritonavir treatment. N Engl J Med. 2022;387(11):1045–1047.
   PubMed Web of Science ®Google Scholar
• Boucau J, Uddin R, Marino C, et al. Characterization of virologic rebound following nirmatrelvir-ritonavir treatment for coronavirus disease 2019 (COVID-19). Clin Infect Dis. 2023;76(3):e526–e529.
   PubMed Web of Science ®Google Scholar
• Wang L, Volkow ND, Davis PB, et al. COVID-19 rebound after Paxlovid treatment during Omicron BA.5 vs BA.2.12.1 subvariant predominance period. medRxiv [Preprint]. 2022:2022.08.04.22278450.
   Google Scholar
• Antonelli G, Focosi D, Turriziani O, et al. Virological and clinical rebounds of COVID-19 soon after nirmatrelvir/ritonavir discontinuation. Clin Microbiol Infect. 2022;28(12):1657–1658.
   PubMed Web of Science ®Google Scholar
• Zhan P, Liu X, Li Z, et al. Design strategies of novel NNRTIs to overcome drug resistance. Curr Med Chem. 2009;16(29):3903–3917.
   PubMed Web of Science ®Google Scholar
• Seley KL, Zhang L, Hagos A. Fleximers.” Design and synthesis of two novel split nucleosides. Org Lett. 2001;3(20):3209–3210.
   PubMed Web of Science ®Google Scholar
• Yates MK, Seley-Radtke KL. The evolution of antiviral nucleoside analogues: a review for chemists and non-chemists. Part II: complex modifications to the nucleoside scaffold. Antiviral Res. 2019;162:5–21.
   PubMed Web of Science ®Google Scholar